Skip to main content
Fig. 3 | Genome Medicine

Fig. 3

From: Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations

Fig. 3

Mean genomic instability index (GII) versus tumor percentage (deduced from ASCAT) before, during, and after treatment, stratified on treatment arms. The top row shows that patients with good response (GR) independent of treatment arms have a higher mean GII, but similar average tumor percentage (bars indicating standard error), than patients with no response (NR) tumors (lower row) before any treatment (blue). After 12 weeks of treatment (pink), the mean GII and tumor percentage drastically gets reduced in the GR tumors (top row), and at the time of surgery (green), more or less all sign of tumor is lost in both treatment arms. Patients not responding to the combination therapy (bottom left plot) show a reduction in mean GII and tumor percentage after 12 weeks of treatment (pink), which halts until time of surgery (green). The bottom right plot reveals that the shift in mean GII and tumor percentage between the three time points is very low for NR tumors in the chemotherapy arm

Back to article page